GHK-Cu · BPC-157 · TB-500 blend

GLOW in Canada

Also known as GLOW blend · GHK-Cu + BPC-157 + TB-500 · GLOW peptide 70 mg · Skin and repair blend

GLOW is a three-peptide blend that puts the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157 and the thymosin-β4 fragment TB-500 in a single 70 mg vial. The rationale is mechanistic: extracellular-matrix remodelling from one component, angiogenic and nitric-oxide signalling from a second, and actin-driven cell migration from a third. No published study has tested the three together; what exists is the separate literature on each. Canada Peptides carries research-grade GLOW as a single lyophilised vial, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Multi-peptide blend (copper tripeptide + gastric pentadecapeptide + thymosin-β4 fragment)
Structure: GHK-Cu (3 aa, copper complex) + BPC-157 (15 aa) + TB-500 (Tβ4 fragment) · 70 mg total peptide per vial
Half-life: Minutes for each component in plasma; tissue effects reported to outlast circulating levels
Route in research: Subcutaneous in the research literature for all three components; GHK-Cu also topical
Cadence in research: Once daily in most animal protocols for each component; no protocol exists for the blend
Storage: Lyophilised: refrigerated, dark. Reconstituted: refrigerated, used within weeks; solution is blue from the copper complex
Status in Canada: No Health Canada market authorisation or DIN for the blend or any injectable component. Research use only

GLOW FAQ

Is GLOW for sale in Canada?

Yes. Research-grade GLOW — a single 70 mg vial combining GHK-Cu, BPC-157 and TB-500 — is available in Canada from Canada Peptides, priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption.

What is in the GLOW peptide blend?

Three peptides in one lyophilised vial: GHK-Cu, the copper-binding tripeptide; BPC-157, the gastric pentadecapeptide; and TB-500, the actin-binding fragment of thymosin β4. The vial holds 70 mg of total peptide, and the per-component split is stated on each lot's certificate of analysis.

What does the research on GLOW show?

Nothing directly — no published study has tested the three peptides together. The rationale rests on separate literatures: GHK-Cu's wound-healing and gene-expression work, BPC-157's large rodent repair literature, and thymosin β4's preclinical and early clinical repair studies. Whether the combination is additive, synergistic or redundant is untested.

What is the difference between GLOW and KLOW?

KLOW adds a fourth peptide, KPV, the anti-inflammatory α-MSH tripeptide, to the GHK-Cu, BPC-157 and TB-500 base. GLOW is the three-component version. Both are single vials rather than separate compounds, so read the composition before assuming equivalence with the standalone products.

How does a blend change the reconstitution math?

The water volume sets the total concentration — 70 mg in 2 mL is 35 mg/mL, or 350 µg per unit on a U-100 syringe — and each component's share of that figure follows from the split on the certificate of analysis. The three amounts are in a fixed ratio; the dosage calculator's blend mode returns a per-unit figure for each.

Why is the reconstituted solution blue?

GHK-Cu is a copper(II) complex, and dissolved copper peptide is blue to violet. That colour is expected. A shift toward brown or green, or cloudiness, is a sign of degradation and the solution should be discarded.

What side effects does the research report?

Each component is described as well tolerated in its animal literature, and none has controlled human injectable safety data. Theoretical concerns include tumour angiogenesis (BPC-157, thymosin β4) and copper load in people with copper-handling disorders (GHK-Cu). Injection-site reactions are the most common report in applied use. The FDA declined to permit BPC-157 and GHK-Cu in compounded medicines in 2023.

Is GLOW legal in Canada?

No component is a controlled substance, but none has Health Canada approval as an injectable and the blend has no DIN. It may be sold for laboratory research, which is how it is sold here. BPC-157 is prohibited under WADA's S0 category and thymosin β4 fragments under S2, so the blend is off-limits for tested athletes.

GLOW in Canada

Quick facts

GLOW — for sale in Canada

What is GLOW?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

GLOW FAQ

Research references